|
|
Other links at Articles > Cardiology |
| 4. |
Dose-Ranging Study of Novel Anticoagulant Promising
|
|
|
The addition of apixaban to antiplatelet therapy resulted in an increase in bleeding, but there was also an observed trend toward a reduction in clinically relevant ischemic events, a new dose-ranging study has shown. Heartwire
|
| 5. |
FDA Safety Changes: Gleevec, Keppra, Neupogen
|
|
|
The FDA has approved revisions to the safety labeling for imatinib mesylate tablets (Gleevec), levetiracetam injection (Keppra), and filgrastim injection (Neupogen). Medscape Medical News
|
|
|
